Odyssey Therapeutics Appoints Jeffrey M. Leiden as Board Chair

Odyssey Therapeutics, Inc. has named industry veteran Jeffrey M. Leiden, M.D., Ph.D., as Chairman of the Board. Dr. Leiden has more than 40 years of experience in the biopharma industry and has dedicated his career to improving the lives of people suffering from serious diseases, most recently as the Executive Chairman and former CEO of Vertex Pharmaceuticals. Dr. Leiden, one of the biopharmaceutical industry’s most admired and accomplished leaders, has discovered, developed, and commercialized some of the most transformative and life-changing medicines in the last two decades. He was instrumental in building Vertex into one of the world’s largest and most profitable biotechnology companies, steering the company toward significant, long-term growth.

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines.

The latest funding round was a Series A for $218M on December 7, 2021.